Of the patients bearing a tumor with BECN1 and BRCA1 shallow deletion (174), 105 (60.4%) of patients were sensitive, 47 (27%) were resistant and 22 (12.6%) developed early resistance. The gene discussed is BRCA1; the disease is neoplasm.